Shandong Jincheng Pharmaceutical and Chemical Co Ltd (300233) - Net Assets
Based on the latest financial reports, Shandong Jincheng Pharmaceutical and Chemical Co Ltd (300233) has net assets worth CN¥3.78 Billion CNY (≈ $553.76 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.21 Billion ≈ $762.53 Million USD) and total liabilities (CN¥1.43 Billion ≈ $208.76 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Shandong Jincheng Pharmaceutical and Che total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.78 Billion |
| % of Total Assets | 72.62% |
| Annual Growth Rate | 18.22% |
| 5-Year Change | 8.27% |
| 10-Year Change | 147.57% |
| Growth Volatility | 50.11 |
Shandong Jincheng Pharmaceutical and Chemical Co Ltd - Net Assets Trend (2008–2025)
This chart illustrates how Shandong Jincheng Pharmaceutical and Chemical Co Ltd's net assets have evolved over time, based on quarterly financial data. Check Shandong Jincheng Pharmaceutical and Che tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Shandong Jincheng Pharmaceutical and Chemical Co Ltd (2008–2025)
The table below shows the annual net assets of Shandong Jincheng Pharmaceutical and Chemical Co Ltd from 2008 to 2025. For live valuation and market cap data, see 300233 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.72 Billion ≈ $544.93 Million |
-2.82% |
| 2024-12-31 | CN¥3.83 Billion ≈ $560.76 Million |
+1.35% |
| 2023-12-31 | CN¥3.78 Billion ≈ $553.29 Million |
+3.33% |
| 2022-12-31 | CN¥3.66 Billion ≈ $535.47 Million |
+6.39% |
| 2021-12-31 | CN¥3.44 Billion ≈ $503.30 Million |
-0.80% |
| 2020-12-31 | CN¥3.47 Billion ≈ $507.37 Million |
-15.12% |
| 2019-12-31 | CN¥4.08 Billion ≈ $597.74 Million |
-0.08% |
| 2018-12-31 | CN¥4.09 Billion ≈ $598.21 Million |
+3.82% |
| 2017-12-31 | CN¥3.94 Billion ≈ $576.20 Million |
+161.78% |
| 2016-12-31 | CN¥1.50 Billion ≈ $220.11 Million |
+14.79% |
| 2015-12-31 | CN¥1.31 Billion ≈ $191.74 Million |
+17.34% |
| 2014-12-31 | CN¥1.12 Billion ≈ $163.40 Million |
+9.30% |
| 2013-12-31 | CN¥1.02 Billion ≈ $149.51 Million |
+4.73% |
| 2012-12-31 | CN¥975.57 Million ≈ $142.76 Million |
+1.74% |
| 2011-12-31 | CN¥958.84 Million ≈ $140.31 Million |
+155.46% |
| 2010-12-31 | CN¥375.33 Million ≈ $54.92 Million |
+33.32% |
| 2009-12-31 | CN¥281.53 Million ≈ $41.20 Million |
+30.04% |
| 2008-12-31 | CN¥216.49 Million ≈ $31.68 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shandong Jincheng Pharmaceutical and Chemical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1533.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥778.26 Million | 21.24% |
| Other Components | CN¥2.89 Billion | 78.76% |
| Total Equity | CN¥3.66 Billion | 100.00% |
Shandong Jincheng Pharmaceutical and Chemical Co Ltd Competitors by Market Cap
The table below lists competitors of Shandong Jincheng Pharmaceutical and Chemical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
REalloys Inc.
NASDAQ:ALOY
|
$744.40 Million |
|
ORIENT SECUR.CO.LTD.H YC1
F:OS9
|
$744.53 Million |
|
Shinyoung Securities Co. Ltd.
KO:001720
|
$744.56 Million |
|
Iperionx Ltd
AU:IPX
|
$744.85 Million |
|
Dalian Sunasia Tourism Holding Co Ltd
SHG:600593
|
$744.06 Million |
|
Shanghai Pudong Road & Bridge Construction Co Ltd
SHG:600284
|
$743.97 Million |
|
Nuh Cimento Sanayi AS
IS:NUHCM
|
$743.53 Million |
|
Marimaca Copper Corp
TO:MARI
|
$743.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shandong Jincheng Pharmaceutical and Chemical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,766,982,000 to 3,663,385,616, a change of -103,596,384 (-2.8%).
- Net income of 44,186,260 contributed positively to equity growth.
- Dividend payments of 162,507,415 reduced retained earnings.
- Other comprehensive income decreased equity by 205,575,793.
- Other factors increased equity by 220,300,565.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥44.19 Million | +1.21% |
| Dividends Paid | CN¥162.51 Million | -4.44% |
| Other Comprehensive Income | CN¥-205.58 Million | -5.61% |
| Other Changes | CN¥220.30 Million | +6.01% |
| Total Change | CN¥- | -2.75% |
Book Value vs Market Value Analysis
This analysis compares Shandong Jincheng Pharmaceutical and Chemical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.39x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 11.14x to 1.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥1.19 | CN¥13.25 | x |
| 2009-12-31 | CN¥1.56 | CN¥13.25 | x |
| 2010-12-31 | CN¥2.08 | CN¥13.25 | x |
| 2011-12-31 | CN¥4.54 | CN¥13.25 | x |
| 2012-12-31 | CN¥3.99 | CN¥13.25 | x |
| 2013-12-31 | CN¥4.19 | CN¥13.25 | x |
| 2014-12-31 | CN¥4.52 | CN¥13.25 | x |
| 2015-12-31 | CN¥5.14 | CN¥13.25 | x |
| 2016-12-31 | CN¥5.68 | CN¥13.25 | x |
| 2017-12-31 | CN¥10.39 | CN¥13.25 | x |
| 2018-12-31 | CN¥10.18 | CN¥13.25 | x |
| 2019-12-31 | CN¥10.40 | CN¥13.25 | x |
| 2020-12-31 | CN¥8.86 | CN¥13.25 | x |
| 2021-12-31 | CN¥8.80 | CN¥13.25 | x |
| 2022-12-31 | CN¥9.37 | CN¥13.25 | x |
| 2023-12-31 | CN¥9.57 | CN¥13.25 | x |
| 2024-12-31 | CN¥9.95 | CN¥13.25 | x |
| 2025-12-31 | CN¥9.54 | CN¥13.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shandong Jincheng Pharmaceutical and Chemical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.61%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.42x
- Recent ROE (1.21%) is below the historical average (8.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 25.22% | 9.42% | 0.91x | 2.94x | CN¥32.39 Million |
| 2009 | 28.90% | 13.91% | 0.84x | 2.46x | CN¥53.20 Million |
| 2010 | 27.87% | 13.78% | 0.79x | 2.55x | CN¥67.09 Million |
| 2011 | 5.84% | 7.10% | 0.56x | 1.46x | CN¥-39.89 Million |
| 2012 | 4.27% | 5.21% | 0.54x | 1.51x | CN¥-55.95 Million |
| 2013 | 6.32% | 7.11% | 0.58x | 1.54x | CN¥-37.57 Million |
| 2014 | 9.73% | 10.34% | 0.59x | 1.60x | CN¥-2.97 Million |
| 2015 | 13.23% | 14.51% | 0.59x | 1.54x | CN¥41.73 Million |
| 2016 | 11.09% | 11.22% | 0.63x | 1.57x | CN¥15.72 Million |
| 2017 | 7.41% | 10.27% | 0.57x | 1.27x | CN¥-100.13 Million |
| 2018 | 6.58% | 8.77% | 0.57x | 1.32x | CN¥-137.08 Million |
| 2019 | 5.00% | 7.27% | 0.50x | 1.38x | CN¥-203.13 Million |
| 2020 | -14.22% | -16.50% | 0.59x | 1.45x | CN¥-832.64 Million |
| 2021 | 3.18% | 3.44% | 0.59x | 1.55x | CN¥-231.46 Million |
| 2022 | 7.58% | 7.80% | 0.60x | 1.62x | CN¥-87.38 Million |
| 2023 | 4.70% | 4.94% | 0.60x | 1.59x | CN¥-196.70 Million |
| 2024 | 5.22% | 5.83% | 0.60x | 1.49x | CN¥-179.92 Million |
| 2025 | 1.21% | 1.61% | 0.53x | 1.42x | CN¥-322.15 Million |
Industry Comparison
This section compares Shandong Jincheng Pharmaceutical and Chemical Co Ltd's net assets metrics with peer companies in the Chemicals industry.
Industry Context
- Industry: Chemicals
- Average net assets among peers: $3,122,551,044
- Average return on equity (ROE) among peers: 19.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shandong Jincheng Pharmaceutical and Chemical Co Ltd (300233) | CN¥3.78 Billion | 25.22% | 0.38x | $744.29 Million |
| North Huajin Chemical Industries Co Ltd (000059) | $129.69 Million | 113.83% | 0.52x | $1.06 Billion |
| Sichuan Chemical Co Ltd (000155) | $13.13 Billion | 3.83% | 1.12x | $3.27 Billion |
| Jiangsu Wujiang China Eastern Silk Market Co Ltd (000301) | $2.28 Billion | 6.38% | 0.38x | $11.88 Billion |
| Zangge Holding Co Ltd (000408) | $6.53 Billion | 18.58% | 0.19x | $18.60 Billion |
| Sichuan Jinlu Group Co Ltd (000510) | $941.87 Million | -18.44% | 0.96x | $1.39 Billion |
| Jilin Gpro Titanium Industry Co Ltd (000545) | $20.93 Million | 89.77% | 15.54x | $366.79 Million |
| Aoyuan Beauty Valley Technology Co Ltd (000615) | $2.65 Billion | -5.08% | 2.56x | $831.78 Million |
| Ningxia Younglight Chemicals Co Ltd (000635) | $1.60 Billion | -41.70% | 0.67x | $370.27 Million |
| Maoming Petro-Chemical Shihua Co Ltd (000637) | $985.33 Million | 1.48% | 0.95x | $285.28 Million |
| Inner Mongolia Yuan Xing Energy Co Ltd (000683) | $2.95 Billion | 30.81% | 1.19x | $3.23 Billion |
About Shandong Jincheng Pharmaceutical and Chemical Co Ltd
Shandong Jincheng Pharmaceutical Group Co., Ltd researches and develops, produces, markets, and sells Cephalosporin pharmaceutical intermediates in China and internationally. It offers medical intermediate, animal nutrition, health care, CMO, CDMO, pharmaceuticals, API, finished dosage, and fine chemicals. The company was founded in 2004 and is based in Zibo, China.